INTRODUCTION
Creutzfeldt-Jakob disease (CJD), kuru and Gerstmann-Str~iussler syndrome are human neurodegenerative diseases that are transmissible to laboratory animals (Gajdusek et al., 1966; Gibbs et al., 1968; Masters et al., 1981 ; Tateishi et al., 1979 Tateishi et al., , 1984b . Scrapie is a similar disease that occurs in sheep. The causative agents of these diseases have not been conclusively identified. Attempts to purify the scrapie agent from hamster brain led to the discovery of a particular protein, named prion protein (PrP) (Prusiner, 1982) . The scrapie form of PrP (PrP so) is the major protein component of the fraction containing the scrapie agent (Prusiner, 1982) ; it aggregates to form amyloid , and makes up the kuru (amyloid) plaque seen in the brains of subjects with scrapie, CJD or Gerstmann-Str~iussler syndrome (Bendheim et al., 1984; Kitamoto et al., 1986b) . Prp was found to be encoded by a cellular gene (Chesebro et al., 1985; Oesch et al., 1985) . Antiserum against PrP detected proteins with an apparent Mr of 33K to 35K, in both normal and scrapie-infected hamster brains (Cho, 1986; Oesch et al., 1985) . In normal (scrapie-uninfected) brains, the product of the PrP gene is a protein designated PrP c (cellular form), which is susceptible to digestion by proteinase K. In contrast, PrP sc is resistant to proteinase K digestion . At present, proteinase K digestion is the only method available to differentiate PrP s~ from PrP c.
It is a matter of controversy whether prions are scrapie agents (Prusiner, 1982) or by-products of scrapie infection that co-purify with scrapie agents (Braig & Diringer, 1985) . One of the arguments raised is whether PrP mRNA and PrP s~ are present in spleen tissue. The infectivity titre is high in the spleen of mice with scrapie (Fraser & Dickinson, 1970 , 1978 ; thus, it would be necessary to identify PrP sc in the spleen if PrP sc is indeed an essential component of the scrapie agent. Some investigators did not detect either PrP mRNA or PrP sc (Chesebro et al., 1985; Czub et al., 1986) , but others have shown that PrP mRNA or PrP sc is present in spleen tissue from subjects with scrapie (Doi et al., 1988; Oesch et al., 1985; Race et al., 1988; Rubenstein et al., 1986; Shinagawa et al., 1986) .
In our initial study with spleens from humans and mice with CJD, we obtained evidence for proteinase-resistant PrP (PrP CJD) in murine, but not in human spleen. Therefore, we examined various organs from these two species with CJD, and noted a different pattern of distribution between human and murine PrP cJD. We also measured PrP cJD concentrations, using a semiquantitative Western blot analysis.
METHODS

Materials.
The cerebral cortex, spinal cord, peripheral nerve, dorsal root ganglion, spleen, liver and lymph node were obtained at autopsy on three Japanese patients with CJD. All tissues were kept at -35 °C. The diagnosis of CJD was made by their clinical course, histopathological examination, and detection of PrP °D in the brain, using a Western blot technique. Transmission of CJD from these three patients to small rodents is now in progress in our laboratory.
New Zealand white (NSW) mice were inoculated intracerebrally (i.c.) with the Fukuoka-1 CJD strain (Tateishi etal., 1979) . The breeding and the experiments were all carried out under specific pathogen-free conditions, using a barrier system set up in the Animal Center in Kyushu University. After about 4 months, the mice were sacrificed by cervical dislocation at the end stage of the illness. Brain stem portions of the mice were examined pathologically, and the organs of mice that exhibited spongiform encephalopathy were studied. The brain, spinal cord, spleen, liver, lymph node, kidney, lung and intestine of mice were all preserved at -35 °C and examined as pooled samples in subsequent experiments.
Purification of PrP ca°. PrP °° was prepared as described (Kitamoto et al., 1986a; Kitamoto & Tateishi, 1988) , with modifications. Various organs from each patient with CJD, and from pooled samples of CJD-infected mice were used. The tissue (wet weight 300 mg) was homogenized in 1 ml of 40 mM-Tris-HCl pH 7-9, 10 mM-NaCI and 6 mM-MgC12 with a glass homogenizer. DNase 1 (150 pg; BDH) was added to the homogenate, and the preparation was incubated at 37 °C for 60 min. One ml 109/o N-lauroylsarcosine (Sarkosyl) was added to the DNase-treated sample and the preparation was rehomogenized. The homogenate was centrifuged at 22000 g for 30 min. The supernatant was then centrifuged at 411000 g for 60 min (CP100H model, RP 100AT4, Hitachi Koki Co.). The pellet was sonicated in 7 ml of 50 mM-Tris-HCl pH 7.6 and 10 ~ NaC1. The sample was centrifuged at 22 000 g for 30 min. The pellet was then sonicated in 1 ml of 50 mM-Tris-HCl pH 7.6 and 10~ NaCI containing 0.6 Ixg of proteinase K (E. Merck), incubated at 37 °C for 60 min, and then centrifuged at 15000g for 30 min. The final pellet was used as the PrP cJ° fraction. Major modifications are the DNase treatment and the ultracentrifugation step. The DNase treatment was added to avoid DNA and Sarkosyl interaction (Doi et al., 1988) . A microultracentrifuge was used for this small-scale purification.
Non-purified tissue preparations. The tissue (wet weight 250 mg) was homogenized in 900 ~tl of 40 mM-Tris-HC1 pH 7.9, I0 mM-NaC1 and 6 mM-MgC12 with a glass homogenizer. DNase I (125 gg) was added to the homogenate and the preparation was incubated at 37 °C for 60 rain. Then 1130 ~t110% Sarkosyl was added to the DNase-treated sample, which was then rehomogenized. The homogenate, to which 125 ~tg of proteinase K had been added, was incubated at 37 °C for 60 min. At the termination of the proteinase digestion, the sample was boiled with 1 volume of Laemmli's sample buffer (62.5 mM-Tris-HC1 pH 6.8, 2% SDS, 5% 2-mercaptoethanol and 5% glycerol) for 5 min.
Western blot analysis. Electrophoresis was performed according to the method of Laemmli (1970) on 15% polyacrylamide gels containing 0.1% SDS. According to the method of Towbin et al. (1979) , proteins were electrophoretically transferred from the gel to Durapore membrane GVHT (Millipore). The blotted membrane was washed with TTBS (25 mM-Tris-HCl pH 7.6, 0-05% Tween 20 and 0.5 M-NaC1) for 10 min, and blocked with TTBS containing 5% low fat milk at 37 °C for 30 min. PrP antiserum against kuru plaque core proteins had been raised in a rabbit (Kitamoto & Tateishi, 1988) . The membrane was then incubated overnight with diluted PrP antiserum (1:1000) in TTBS containing 5% low fat milk at 37 °C. After washing with TTBS, the membrane was reacted with diluted anti-rabbit IgG-alkaline phosphatase conjugate (1:7500; Promega Biotec) in TTBS containing 5% low fat milk at 37 °C for 30 min. After a rinse with TTBS, the colour was developed with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (Promega Biotec) for 90 s. Molecular standard proteins were purchased from Pharmacia.
At first, Western blot analysis was performed with PrP c J° fractions from 300 mg of various human and murine organs in each lane. Next, we measured PrP °D concentrations in organs, using serial dilutions (fractions from 100, 30, 10, 3, 1, 0.3, 0.1 and 0.03 mg wet weight tissue in each lane). For non-purified tissue preparations, serially diluted samples (1, 0.3, 0-1, 0.03, 0-01, 0.003 and 0-001 mg wet weight tissue in each lane) were applied. As a measure of the amount of PrP cJD, we determined the minimum amount (wet weight) of tissue necessary for visualization of the immunolabelled bands.
Affinity-purified antibodies and immunostaining. To check the specificity of immunolabelled bands, we obtained antibodies on the Durapore membrane, according to Talian et al. (1983) . Portions of the blotted membrane strip corresponding 18K to 32K were cut off and incubated overnight at 37 °C with diluted PrP antiserum (1 : 1000) in TTBS containing 5~ low fat milk. After rinsing with TTBS, the bound antibodies were eluted with 1 ml of 0.2 Mglycine-HC1 pH 2-5 and immediately neutralized with 100 p.1 of 1.5 M-Tris base.
With formic acid enhancement on tissue sections, as described , we examined formalinfixed, paraffin-embedded serial sections of CJD-infected mouse tissues containing numerous kuru plaques (Tateishi et al., 1984a . The affinity-purified antibodies were used as primary antibodies and the following steps were performed with unlabelled antibodies using the biotin-streptavidin method (Stravigen, BioGenix Laboratories).
RESULTS
PrP c J° recovery
To estimate the PrP cJ° recovery, we compared the data on PrP cJD purification with that from the non-purified tissue preparations. In the human CJD brain, the minimum wet weight for a positive immunolabelling of PrP cJD was 0-3 to 1 mg in the purified PrP cJD fractions, and was 0.03 to 0.1 mg in the non-purified preparations (Fig. 1) . The bands revealed major proteins of 27K to 31K, 23K to 25K and 19K to 21K, and a minor one of 16K to 18K. In the spleens of humans with CJD, we found no positive immunoreactions, either in the purified PrP cJD fractions or in the non-purified tissue preparations. With murine CJD brains, positive labelling was seen in 0-3 mg of the PrP cJD fractions or in 0.03 mg of the non-purified preparations. In the CJD-infected mice, the spleen had a relatively high PrP cJD concentration (see below). With spleen tissue from the CJD-infected mice, a positive labelling was seen in 1 to 3 mg of the purified PrP cJD fractions and in 0.1 to 0.3 mg of the non-purified preparations. Therefore, we estimated the PrP cJD recovery to be about 10~. The non-purified preparations (1 mg wet weight) from thymus and intestine in the CJD-infected mice showed no or only weakly immunolabelled bands.
With a Western blot analysis, there is the disadvantage of volume limitation for each well in the polyacrylamide gels, a problem especially in the case of non-purified tissue preparations (maximum 1 mg wet weight in a well). In the purified PrP cJ° fractions, we could apply the final pellet from more than 300 mg tissue to each well. The examination with the purfied PrP cJD fractions covers a wider range of 0.3 to 300 mg wet weight than did that with the non-purified preparations (0.03 to I mg). Therefore, the organ distribution of PrP cJD was examined using the purified PrP cJD fractions.
To find the sensitivity of our Western blot analysis, we obtained gel-eluted PrP cJ°. To purify the 23K to 25K band of human PrP cJD, SDS-PAGE and electroelution were performed according to the methods of Hope et al. (1988) . Proteins were eluted for 5 h from a gel slice with a electroelutor (Bio-Rad) and purified by high-performance liquid chromatography (TSK 3000SW, 0.75 x 60 cm). Then, we examined this eluted PrP cJD using Western blot analysis. The minimum PrP cJD content of a positive immunolabelling was 0-3 ng of gel-eluted PrP cJD (Fig. 2) .
PrP c J° distribution in humans
The organ distribution of human PrP cJD is summarized in Table 1 . Positive reactions were found in PrP cm fractions of the central nervous system (cerebral cortex and spinal cord). Minimum wet weight of positive labelling was 0.3 mg in the PrP cJD fraction of brain tissues from two of the patients and 1 mg from the other. In spinal cord tissue, a positive reaction was seen in 3 mg of the PrP cJD fraction from two of the patients, and in 10 mg from the other. In each case, the PrP cJD concentration in the spinal cord was 10~ of that in the cerebral cortex. There were no immunolabeUed bands in purified PrP cJD fractions from 300 mg of non-neuronal organs (spleen, liver and lymph node) and peripheral nervous systems (dorsal root ganglion and peripheral nerves). In addition to these three CJD cases, we examined two other spleen tissues from patients with CJD, and from whom the disease has been transmitted to mice . However, there was no positive immunolabelling of the purified PrP cJD fractions or of the non-purified tissue preparations from various organs of non-CJD control cases.
PrP cJD distribution in mice
The organ distribution of murine PrP cJD in CJD-infected mice is summarized in Table 2 . Positive data in the Western blot analysis were obtained from the PrP cJ° fractions from the central nervous system, spleen, lymph node, thymus and intestine. M i n i m u m wet weight for positive labelling was 0.3 mg of brain, 1 to 3 mg of spleen, 3 mg of spinal cord, 3 mg of lymph node, 10 mg of thymus, and 10 to 30 mg of intestine (Fig. 3) . The pattern of immunolabelling showed three major proteins of 27K to 31K, 23K to 25K and 20K to 22K. There were no immunolabelled bands in purified PrP cJD fractions from 300 mg of liver, lung and kidney of the CJD-infected mice. There was also no positive immunolabelling of the purified PrP cm fractions and the non-purified tissue preparations from control (non-CJD) mice. 
PrP c J° fractions from non-neuronal organs may share the epitopes of antigens in kuru plaques
T o check the specificity o f the immunolabelled bands on the blotted m e m b r a n e , we carried out affinity purification o f antibodies bound on the m e m b r a n e . D u r a p o r e m e m b r a n e strips containing the purified PrP cJD fractions from 30 m g of brain, 120 m g of spleen and 120 m g o f liver in C J D -i n f e c t e d mice were used as solid-phase antigens for the purification. The PrP cJ° fraction from the brain was used as a positive control, and the fraction from the liver as a negative one, because we detected PrP i m m u n o r e a c t i o n s from brain, but not from liver. W e e x a m i n e d the fraction from the spleen. The antibodies eluted from the brain fraction stained typical birefringent kuru plaques in C J D -i n f e c t e d murine brain (Fig. 4a) . H o w e v e r , antibodies eluting from the liver fraction did not i m m u n o l a b e l murine kuru plaques in the adjacent section (Fig. 4b) . O n the other hand, antibodies eluted from the spleen fraction stained routine kuru plaques in the serial sections (Fig. 4c) . The staining with the spleen fraction eluted antibodies was of a lesser intensity than that with the brain fraction eluted antibodies. For a comparison with tissues from autopsied humans with CJD, murine PrP cJD distribution was examined at the end stage of the illness. Human PrP cJD was restricted to the central nervous system. PrP cJD concentration in the central nervous system of mice was almost identical to that in humans. In addition, murine PrP cJD was detected in the lymphoreticular organs. PrP cJD in murine spleen had the same epitopes as in murine kuru plaques. The intestine also is rich in lymphoid tissue, i.e. Peyer's patches. The failure to detect PrP ¢J° in human lymphoreticular organs may have been due to a low recovery of PrP cJ° in the purification processes, a different sensitivity to proteinase K digestion, a low affinity of our PrP antiserum, or a low PrP cJD concentration. There were no positive labellings in the non-purified human spleen preparations, this result differing from the findings in the murine spleen. Concerning the sensitivity to proteinase K digestion in the human spleen, the abnormal form of PrP cannot at present be differentiated from the normal cellular form without proteinase K digestion. Our PrP antiserum was raised against kuru plaque core protein purified from a patient with Gerstmann-Str/iussler syndrome. This antiserum had the highest affinity of all our PrP antisera (Kitamoto et al., 1986 b; Kitamoto & Tateishi, 1988) , and cross-reacts with murine PrP cm (Kitamoto et al., 1989) . Murine PrP cJD in the spleen was readily recognized by its interspecies cross-reactivity, but human PrP cJD in the spleen was not immunolabelled. As it is unlikely that the negative result is due to a low affinity of PrP antiserum for human PrP cJD, it seems that the human spleen has a lower concentration of PrP cJD than does the murine spleen. Within the limits of our method, it was demonstrated that the distribution pattern of murine PrP cm differs from that in humans.
Intensive studies of the infectivity titres from various organs have been done on scrapieinfected mice (Eklund et al., 1967) , scrapie-infected goats (Hadlow et al., 1974) and CJDinfected mice (Kuroda et al., 1983) . Murine prpCJD-positive organs at the end stage of CJD were the brain, spinal cord, spleen, lymph node, thymus and intestine, and prpCJD-negative organs were the liver, kidney and lung. In 1967, Eklund et al. reported that the LDso in scrapie-infected mice at 42 weeks after subcutaneous inoculation was 0.03 ml of a 107.4 dilution in brain, 106.6 in spinal cord, 105.5 in spleen, 104.6 in lymph node, 104.5 in thymus, 104.5 in intestine, 103.8 in lung and 101 in kidney and liver. We detected PrP cJD in organs which had a higher titre than 104.5 LDso/0.03 ml, but could not detect it in organs below 103.8 LDso/0"03 ml infectivity. The PrP cJD concentration correlates well with the infectivity titre in various organs.
It is impossible to evaluate the infectivity titre of human CJD because human to human transmission is not feasible. However, our experiment involving transmission from humans to mice revealed that the transmissibility of CJD from brains was higher than from the spleen . There are reports that the infectivity in the spleen differed with the species (Hadlow et al., 1974; Kimberlin & Walker, 1977) . Mouse spleen had a titre of 105 to 106 LDso i.c. units/0-05 g, while hamster spleen had a lower titre ranged from 102.3 to 104.3 LDs0 i.e. units/0-05 g in 'Chandler' scrapie (Kimberlin & Walker, 1977) . The spleen tissue of the scrapieinfected goat is also less infective (Hadlow et al., 1974) . Therefore, the PrP concentration and infectivity titre in non-neuronal organs may differ with the species; however, PrP cJ° concentrations and the infectivity titre in various murine organs seem to correlate.
